Navigation Links
TGen-led research shows ability to do next-generation sequencing for patients with advanced cancers
Date:10/30/2013

SCOTTSDALE, Ariz. Oct. 30, 2013 A pilot study led by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare shows that, even for patients with advanced and rapidly transforming cancer, researchers can find potential therapeutic targets using the latest advances in genomic sequencing.

Sequencing spells out, or decodes, the billions of letters of DNA and other genomic data so that clinicians can discover what genetic changes might lead to cancer.

Better optics and faster computers, which are the hallmarks of today's Next Generation Sequencing (NGS), are leading to genomic analysis that enables development of new drugs that target specific genetic mutations. However, because patients' tumors often contain multiple abnormalities, their cancer often progresses beyond initial targeted therapies.

Researches showed that the most cutting-edge NGS whole genome sequencing (WGS), and even more advanced whole transcriptome sequencing (WTS) can reveal larger numbers of targets in an individual's tumor, and that these "could be addressed using specific therapeutic agents, and perhaps reduce the chance of progression," according to the pilot study published today in the scientific journal PLOS ONE.

The study A Pilot Study Using Next Generation Sequencing in Advanced Cancers: Feasibility and Challenges reported results on nine patients evaluated at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership of Scottsdale Healthcare and TGen.

"Patients with advanced cancer often exhaust treatment options. Targeting a single abnormality is not sufficient to prevent progression," said Dr. Glen Weiss, an Associate Professor in TGen's Cancer and Cell Biology Division and the study's lead author.

"We demonstrate the feasibility of using NGS in advanced cancer patients so that treatments for patients with progressing tumors may be improved," said Dr. Weiss, who previously was affiliated with Scottsdale Healthcare, and now is affiliated with Cancer Treatment Centers of America Western Regional Medical Center in Arizona.

For all nine patients, WGS was used to compare their germline DNA from white blood cells (the DNA an individual is born with) to the DNA from their tumor cells. For six of these patients, researchers also used WTS to sequence their total RNA isolated from the tumor, and compare that to total RNA from non-patient controls.

"Based on our findings, we found it was feasible to perform these advanced NGS technologies for patients in a clinical trial situation," said Dr. Daniel Von Hoff, TGen Distinguished Professor and Physician In Chief; Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials; and one of the senior authors of the study.

In addition to identifying as many genomic changes as possible, a secondary objective of this pilot study was to develop a workflow process from tumor biopsy to treatment.

"This process must occur in a short enough timeframe in order for patient to benefit from this additional information in developing a treatment plan," the study said.

Some of the challenges include: NGS reporting delays, communication of results to out-of-state participants and their treating oncologists, and chain of custody handling from fresh biopsy samples for CLIA (Clinical Laboratory Improvement Amendments) target validation.

The study also showed that WGS and WTS both have advantages, and that newer technological strategies may capture the best of both.

"With improved efficiencies that decrease the time to get NGS results and at reasonable costs, we can envision how NGS might be applied more globally to advanced cancer patients," said Dr. John Carpten, TGen Deputy Director and also a senior author of the study. "Even during the relatively short time that this study was enrolling, we observed significant improvements in sequencing analyses and lower costs."

The study was funded by the National Foundation for Cancer Research (NFCR).

"We must be able to identify all causes of cancer. Working with TGen, we are pursuing this goal at a level that is unmatched," said NFCR President Franklin C. Salisbury Jr. "The world needs to know that, through the use of 21st Century medicine, we are on our way to conquering cancer."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. TGen-led study discovers dramatic changes in bacteria following male circumcision
2. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
3. Research reveals first evidence of hunting by prehistoric Ohioans
4. Diabetes Research Institute develops oxygen-generating biomaterial
5. APS issues new policy requiring identification of sex or gender in reporting scientific research
6. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
7. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
8. U of Alberta researcher steps closer to understand autoimmune diseases
9. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
10. A project to research biological and chemical aspects of microalgae to fuel approach
11. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation ... and Border Protection (CBP) is testing its biometric identity ... San Diego to help identify certain non-U.S. citizens ... . The test, designed to help determine the efficiency and ... began in February and will run until May 2016. ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a leading designer, ... announced the completion of a significant transaction and partnership that positions Amendia for ... partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm specializing ...
(Date:4/29/2016)... CO (PRWEB) , ... April 29, 2016 , ... ... addressing the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, ... growth. Mr. Kelley, a recognized leader and mentor in the Denver area ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced ... FDA via 510(k) for sale in the United States. These components expand the ... fusions. With one-level sales beginning in October of 2015, the company has seen ...
(Date:4/28/2016)... 28, 2016 The report "Cryocooler ... Cryocoolers), Service (Technical Support, Product Repairs & Refurbishment, Preventive ... Forecast to 2022", published by MarketsandMarkets, the global market ... 2022, at a CAGR of 7.29% between 2016 and ... and 94 Figures spread through 159 Pages and in-depth ...
Breaking Biology Technology: